Real-World data shows Tirabrutinib's promise for rare brain cancer

NCT ID NCT06714370

Completed Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen May 26, 2026 · Last updated Jun 11, 2026 · Updated 5 times

Summary

This study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see how many patients had their tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Chang Gung Memorial Hospital

Kaohsiung City, Taiwan
Chang Gung Memorial Hospital

Taoyuan, Taiwan
China Medical University Hospital

Taichung, Taiwan
National Cheng Kung Univeristy Hospital

Tainan, Taiwan
National Taiwan University Hospital

Taipei, Taiwan
Taipei Veterans General Hospital

Taipei, Taiwan

Conditions

The condition(s) this trial relates to.

brain cancer lymphoma Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)